Company · ALT
Altimmune, Inc.
Nasdaq's symbol directory lists ALT on Nasdaq as “Altimmune, Inc. - Common Stock”.
In the 12 months to Nov 19, 2026: insiders bought on 5 occasions ($141K); 2 filings by holders of 5% or more; 4 company reports (Form 8-K, since May 26, 2026).
Insider trades · SEC Form 4
Those inside the hall
Open-market purchases and sales only. Legs one person filed for one day are combined.
Who traded
- Durso Jerome Benedict, President and CEO bought $94K
- Pisano Wayne bought $16K
- Gregory L. Weaver, Chief Financial Officer bought $16K
- MENZIUSO RICHARD THOMAS, Principal Accounting Officer bought $14K
Every trade (5)
- BUYMENZIUSO RICHARD THOMAS, Principal Accounting Officer bought $14K
- BUYDurso Jerome Benedict, President and CEO bought $50K
- BUYPisano Wayne bought $16K
- BUYGregory L. Weaver, Chief Financial Officer bought $16K
- BUYDurso Jerome Benedict, President and CEO bought $44K
Large holders · SEC Schedules 13D and 13G
Five percent and over
Anyone who comes to hold more than 5% of a company's voting shares must tell the SEC. A Schedule 13D is filed by a holder who may seek to influence the company; a 13G by one who states it is a passive investor. An amendment updates an earlier filing, and a stake reported as 0% means the holder says it has sold all, or nearly all, of its shares. Every recent 13D and 13G
- TCG Crossover GP II, LLC 4.9%
- STATE STREET CORPORATION 4.3%
Company reports · SEC Form 8-K
In its own words
Current reports the company filed with the SEC; most items are due within four business days of the event. Each line lists the report's items by the SEC's own titles; the filing says what happened. Reports collected since May 26, 2026; every 8-K at the SEC.
- Results of operations and financial condition Nov 12, 2026
- Creation of a direct financial obligation Oct 29, 2026
- Departure or appointment of directors or officers; Regulation FD disclosure Oct 27, 2026
- Departure or appointment of directors or officers Sep 29, 2026
Sources: SEC EDGAR (Forms 4, 144 and 8-K) and STOCK Act periodic transaction reports. Filings can be late, amended or wrong at the source; see methodology.